Association between oral JAK-1 inhibitors and infection risks in atopic dermatitis: a retrospective analysis of the FAERS database
BackgroundJanus kinase (JAK)-1 inhibitors have been approved for moderate-to-severe atopic dermatitis (AD). Despite favorable efficacy, their real-world infection risk profile requires further investigation.MethodsWe conducted a retrospective disproportionality analysis using the U.S. Food and Drug...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-11-01
|
| シリーズ: | Frontiers in Medicine |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1694688/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|